AH Bio Fund II, L.P. insider trades
AH Bio Fund II, L.P. has filed 2 Form 4s with the SEC that we hold, for Nautilus Biotechnology, Inc. (NAUT) (10% owner) and Scribe Therapeutics, Inc. (SCTX) (10% owner). Across all of them we count 1 purchase worth $5.0M and 2 sales worth $11.8M reported on Form 4. In the last 12 months: 1 purchase ($5.0M) and 2 sales ($11.8M). The largest single trade was a sale of 4,615,974 shares of Nautilus Biotechnology, Inc. worth $10.8M, dated 2026-06-02. The first filing on our record is dated 2026-06-04 and the latest 2026-07-29.
Nautilus Biotechnology, Inc. (NAUT)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-06-02 | S, sale reported on Form 4 | 4,615,974 | $10.8M | 2026-06-04 |
| 2026-06-02 | S, sale reported on Form 4 | 384,026 | $902.5K | 2026-06-04 |
Scribe Therapeutics, Inc. (SCTX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-07-27 | P, purchase reported on Form 4 | 333,333 | $5.0M | 2026-07-29 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1725721) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms